Global Radiotheranostics Market By radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-167, andOthers), Application (Oncology and Non-Oncology) – Industry Trends and Forecast to 2031.
Radiotheranostics Market Analysis and Size
Radiotheranostics agents are used primarily in nuclear medicine for both imaging (diagnosis) and therapy of various diseases, particularly cancer. The concept revolves around targeting specific receptors or molecules present in diseased tissues with a radioactive component, thereby enabling both imaging to visualize the extent and nature of the disease and therapy to treat it.
Data Bridge Market Research analyzes that the global radiotheranostics market which was USD 5019.2 million in 2023, is likely to reach up to USD 13316.6 million by 2031, and is expected to undergo a CAGR of 14.2% during the forecast period. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016 - 2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-167, and Others), Application (Oncology and Non-Oncology)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Novartis AG (Germany), Bayer AG (Germany), Telix Pharmaceuticals Limited (Australia), ITM Radiopharma (Germany), RadioMedix (U.S.), IsoTherapeutics Group, LLC (U.S.), and Q BioMed Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Radiotheranostics is an emerging medical field that combines therapeutic and diagnostic capabilities within a single radiopharmaceutical agent. The term "radiotheranostics" is a portmanteau of "radiotherapy" and "diagnostics." In radiotheranostics, a radioactive component is incorporated into a molecular compound that selectively binds to specific receptors or molecules in diseased tissues. This allows for both imaging (diagnosis) and therapy of various diseases, particularly cancer, with high precision.
Radiotheranostics Market Dynamics
Drivers
- Increasing Incidence of Cancer
The increasing prevalence of cancer and other diseases necessitates more effective diagnostic and therapeutic approaches. Radiotheranostics offers a targeted and personalized approach to treatment, potentially improving outcomes and reducing side effects compared to conventional therapies. With the increasing prevalence of cancer worldwide, there's a growing need for more effective and targeted treatment options and this will in turn drive the market.
- Personalized Medicine
There is a growing recognition of the importance of personalized medicine, which aims to tailor medical treatment to the individual characteristics of each patient. Radiotheranostics aligns with this trend by enabling the delivery of targeted therapy based on the specific molecular profile of a patient's disease. Radiotheranostics allows for a more personalized approach to cancer treatment. By using imaging techniques to identify specific molecular targets on cancer cells, physicians can tailor treatment strategies to individual patients.
Opportunities
- Advancements in Imaging Technology
The continuous evolution of imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) has significantly enhanced the ability to visualize and characterize diseases at a molecular level. This has expanded the scope of radiotheranostics by enabling more accurate diagnosis and staging of diseases. Advancements in imaging technology have played a significant role in the development and application of radiotheranostics for cancer treatment. These technological advancements have enabled more precise targeting of tumors, better visualization of disease progression, and improved monitoring of treatment response.
- Growing Research and Development Activities
Research and development (R&D) activities in the field of radiotheranostics are essential for advancing the capabilities and applications of this innovative approach to disease diagnosis and treatment. These activities encompass a wide range of efforts to develop novel radiopharmaceutical agents, optimize imaging techniques, refine therapeutic protocols, and explore new applications across different disease areas.
Restraints/Challenges
- Regulatory Hurdles
The regulatory approval process for new radiopharmaceuticals can be complex and time-consuming. Radiotheranostic agents must undergo rigorous evaluation for safety, efficacy, and quality assurance, which may delay their clinical translation and market availability. Radiotheranostic agents are subject to regulatory approval by agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe. Obtaining approval for new radiopharmaceuticals can be a lengthy and expensive process, requiring extensive preclinical and clinical data to demonstrate safety and efficacy. Regulatory agencies may also require additional studies to establish the optimal dosage, administration route, and patient selection criteria for radiotheranostic agents.
- Cost and Budget Constraints
Radiotheranostic procedures may be costly due to the expenses associated with radiopharmaceutical production, imaging equipment, and specialized personnel. Reimbursement policies and coverage limitations by healthcare payers may present financial barriers to patient access and healthcare provider adoption. The high cost associated with radiotheranostics can indeed pose a significant barrier to its widespread adoption and market growth. Several factors contribute to the high cost of radiotheranostic procedures, including research and development expenses, production costs, regulatory requirements, and reimbursement challenges.
This radiotheranostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the radiotheranostics Market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Radiotheranostics Market Scope
The radiotheranostics market is segmented on the basis of radioisotope and applications. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Radioisotope
- Iodine-131
- Iodine-123
- Gallium-68
- Lutetium-167
- Others
Application
- Oncology
- Non-Oncology
Radiotheranostics Market Regional Analysis/Insights
The radiotheranostics market is analysed and market size insights and trends are provided by country, radioisotope and application as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
North America is expected to dominate the market due to the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people with cancer.
Asia-Pacific is expected to witness significant growth due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Radiotheranostics Market Share Analysis
The radiotheranostics market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Novartis AG (Germany)
- Bayer AG (Germany)
- Telix Pharmaceuticals Limited (Australia)
- ITM Radiopharma (Germany)
- RadioMedix (U.S.)
- IsoTherapeutics Group, LLC (U.S.)
- Q BioMed Inc. (U.S.)
SKU-